Jade Biosciences, Inc.
JBIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001798749
No open-market purchases or sales by Jade Biosciences, Inc. insiders were filed in the last 90 days; 153 institutions reported holding it in 13F filings for Q2 2026, worth $1.62B in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in Jade Biosciences, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 105
- +27 vs. Q3 2025
- Shares held
- 47.1M
- +15.5M (+48.9%) vs. Q3 2025
- Total value
- $726.3M
- +$453.4M (+166.2%) vs. Q3 2025
- New holders
- 33
- 44 more added
- Sold out
- 6
- 14 more reduced
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting JBIO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 153 | $1.62B |
| Q1 2026 | 120 | $700.3M |
| Q4 2025 | 105 | $726.3M |
| Q3 2025 | 78 | $272.9M |
| Q2 2025 | 75 | $315.1M |
| Q1 2025 | 82 | $79.6M |
| Q4 2024 | 80 | $79.9M |
| Q3 2024 | 75 | $57.8M |
| Q2 2024 | 81 | $45.1M |
| Q1 2024 | 81 | $841.5M |
| Q4 2023 | 64 | $637.8M |
| Q3 2023 | 58 | $386.3M |
| Q2 2023 | 60 | $488.3M |
| Q1 2023 | 66 | $524.1M |
| Q4 2022 | 70 | $802.9M |
| Q3 2022 | 56 | $447.4M |
| Q2 2022 | 51 | $403.0M |
| Q1 2022 | 46 | $475.5M |
| Q4 2021 | 47 | $301.6M |
| Q3 2021 | 41 | $452.6M |
| Q2 2021 | 18 | $454.4M |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Jade Biosciences, Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| VR Adviser, LLC | 3,220,364 | $49.7M | 2.45% | 00.0% | Unchanged |
| Bellevue Group AG | 3,341,103 | $51.6M | 0.98% | +3,341,103 | New |
| Ra Capital Management, L.P. | 3,671,083 | $56.6M | 0.58% | +2,608,757+245.6% | Added |
| Fairmount Funds Management LLC | 4,553,494 | $70.3M | 5.35% | +1,333,126+41.4% | Added |
| FMR LLC | 6,894,488 | $106.4M | 0.01% | +2,005,707+41.0% | Added |
| Deep Track Capital, LP | 0 | $0 | 0.00% | −2,279,892−100.0% | Sold out |
| Frazier Life Sciences Management, L.P. | 0 | $0 | 0.00% | −1,413,280−100.0% | Sold out |
| Deerfield Management Company, L.P. (Series C) | 0 | $0 | 0.00% | −531,163−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −17,653−100.0% | Sold out |
| CI Private Wealth, LLC | 0 | $0 | 0.00% | −11,741−100.0% | Sold out |
| Principal Securities, Inc. | 0 | $0 | 0.00% | −5−100.0% | Sold out |